Biogen (XSWX:BIIB) Other Long-Term Liabilities: CHF514 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIIB Biogen Inc XSWX:BIIB
73 GF Score
Price CHF173.46
GF Value CHF166.94
! 9 Warning Signs
View Full Analysis

What is Biogen Other Long-Term Liabilities?

Biogen XSWX:BIIB 73 Other Long-Term Liabilities is CHF514 Mil as of Jun. 2026. GuruFocus rates XSWX:BIIB with a GF Score™ of 73/100 and a GF Value™ of CHF166.94. The stock has 9 warning signs investors should review.

Biogen's other long-term liabilities for the quarter that ended in Jun. 2026 was CHF514 Mil.

Biogen's quarterly other long-term liabilities declined from Dec. 2025 (CHF596 Mil) to Mar. 2026 (CHF483 Mil) but then increased from Mar. 2026 (CHF483 Mil) to Jun. 2026 (CHF514 Mil).

Biogen's annual other long-term liabilities declined from Dec. 2023 (CHF675 Mil) to Dec. 2024 (CHF653 Mil) and declined from Dec. 2024 (CHF653 Mil) to Dec. 2025 (CHF596 Mil).

Biogen Other Long-Term Liabilities Related Terms

Biogen Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Biogen's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Other Long-Term Liabilities Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,216.18 879.62 675.49 652.92 596.48

Biogen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 515.97 475.35 596.48 482.54 514.27
XSWX:BIIB
73GF Score
Biogen Inc XSWX:BIIB
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of CHF514 Mil mean?
Biogen (XSWX:BIIB) has a Other Long-Term Liabilities of CHF514 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Biogen and its competitors.
Is Biogen's Other Long-Term Liabilities too high?
Biogen's current Other Long-Term Liabilities is CHF514 Mil. Overall, Biogen has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Biogen's Other Long-Term Liabilities compare to OGN and AMRN?
Biogen's Other Long-Term Liabilities of CHF514 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Biogen and its competitors. Biogen's current Other Long-Term Liabilities is CHF514 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Biogen (XSWX:BIIB) has a current Other Long-Term Liabilities of CHF514 Mil. The stock's GF Value™ is CHF166.94, compared to a current price of CHF173.46 — trading 3.9% above its estimated fair value. The current Other Long-Term Liabilities is CHF514 Mil. Biogen's overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Biogen (XSWX:BIIB), the current Other Long-Term Liabilities is CHF514 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (XSWX:BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of CHF173.46 is trading 3.9% above its estimated GF Value™ of CHF166.94.

Key valuation signals for XSWX:BIIB:

  • Other Long-Term Liabilities: CHF514 Mil
  • GF Value™: CHF166.94 vs. price of CHF173.46 (3.9% above fair value)
  • GF Score™: 73/100 with 9 warning signs

No single metric tells the full story. See the XSWX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
73GF Score

Get the complete analysis for XSWX:BIIB

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF173.46
Price
CHF166.94
GF Value